Lifeward Ltd. (LFWD) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Lifeward Ltd. is a medical device company focused on physical rehabilitation and recovery, recently expanding into biomedical technologies. Key products include the ReWalk exoskeleton for spinal cord injury and AlterG Anti-Gravity systems. The company operates as a single reporting segment with primary markets in the United States and Europe.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $6.62 million | $10.55 million | $10.76 million |
| Gross Profit | $2.71 million | $4.05 million | $4.63 million |
| Gross Margin | 40.9% | 38.4% | 43.1% |
| Net Loss | $(11.52) million | $(22.31) million | $(11.40) million |
| Operating Cash Flow | N/A | $(9.68) million | $(9.43) million |
| Cash & Equivalents (End of Period) | $9.45 million | $9.45 million | N/A |
| Convertible Notes (Long-Term) | $4.43 million | $4.43 million | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2026 revenue increased 16% year-over-year to $6.62 million, driven by higher AlterG unit shipments in the U.S. and increased ReWalk sales in Europe. However, YTD revenue decreased 2% due to Q1 supply chain constraints.
- Margin Compression: Gross margin declined to 40.9% in Q2 (from 43.9% in Q2 2025) and 38.4% YTD (from 43.1% YTD 2025). This was caused by adverse foreign exchange fluctuations, higher tariffs, increased component costs, and revenue sharing expenses related to the Oratech transaction.
- Significant R&D Increase: R&D expenses surged to $7.60 million YTD 2026 (up $5.9 million from prior year). This includes a one-time $4.9 million charge for acquired in-process research and development (IPR&D) from the Oratech acquisition, plus clinical trial costs.
- Financial Expenses: Net financial expense increased to $7.81 million YTD 2026, primarily due to non-cash fair value changes in warrant and derivative liabilities and interest on new convertible notes.
- Acquisitions: Completed the acquisition of Oratech Pharmaceuticals (March 2026) and Skelable Ltd. assets (May 2026), expanding the company's pipeline into oral insulin delivery and upper-body robotics.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. Despite recent financing, existing cash resources are deemed insufficient to fund planned operations without additional capital.
- Recent Financing: On July 6, 2026 (subsequent to period end), the company closed a financing transaction issuing $5.6 million in senior secured convertible notes, with an additional $5.6 million available upon meeting specific milestones (sales increase or stock price targets).
- Strategic Focus: Future growth is expected to be driven by ReWalk reimbursement expansion (Medicare and commercial payors), AlterG penetration in rehabilitation clinics, and the clinical advancement of the ORMD-0801 oral insulin candidate.
- Risks: Key risks include reliance on third-party manufacturers (Cirtronics for AlterG), supply chain disruptions, the need for continued capital raises, and the success of clinical trials for new assets.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $9.45 million cash balance against the stated "substantial doubt" regarding the 12-month going concern status.
- Debt Obligations: Review the terms of the $10 million aggregate principal amount of "New Notes" (8% interest, convertible at $5.40/share) and the $1.025 million "Additional Notes" (24% interest) to understand repayment schedules and dilution risks.
- Related Party Transactions: Scrutinize the financial impact of the Oratech acquisition and ongoing revenue sharing/clinical trial service agreements with Oramed Pharmaceuticals Inc.
- Reimbursement Progress: Monitor updates on Medicare coverage for ReWalk and the impact of the recent Administrative Law Judge ruling on future revenue recognition.
- Derivative Liabilities: Confirm the reclassification of warrant and derivative liabilities to equity and the impact of fair value changes on reported net loss.